Loading clinical trials...
Loading clinical trials...
A Randomized, Controlled, Open-label, Prospective Trial of S-1 Plus Gefitinib Versus Gefitinib Monotherapy for First-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With EGFR-sensitive Mutation
Conditions
Interventions
S-1 plus Gefitinib
Gefitinib
Locations
1
China
Henan Cancer Hospital
Zhengzhou, Henan, China
Start Date
March 28, 2018
Primary Completion Date
October 31, 2020
Completion Date
October 31, 2021
Last Updated
July 10, 2020
Lead Sponsor
Henan Cancer Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions